JP7458032B2 - 出血およびセンタキンによる蘇生後のエンドセリン受容体の変化 - Google Patents

出血およびセンタキンによる蘇生後のエンドセリン受容体の変化 Download PDF

Info

Publication number
JP7458032B2
JP7458032B2 JP2020561786A JP2020561786A JP7458032B2 JP 7458032 B2 JP7458032 B2 JP 7458032B2 JP 2020561786 A JP2020561786 A JP 2020561786A JP 2020561786 A JP2020561786 A JP 2020561786A JP 7458032 B2 JP7458032 B2 JP 7458032B2
Authority
JP
Japan
Prior art keywords
centaquine
blood
pharmaceutical composition
renal
rats
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020561786A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523125A (ja
JPWO2019213558A5 (https=
JP2021523125A5 (https=
Inventor
アニル グラティ，
マニシュ ラヴハル，
バウナ カティア，
アビシェーク クマール シン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmazz Inc
Original Assignee
Pharmazz Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmazz Inc filed Critical Pharmazz Inc
Publication of JP2021523125A publication Critical patent/JP2021523125A/ja
Publication of JPWO2019213558A5 publication Critical patent/JPWO2019213558A5/ja
Publication of JP2021523125A5 publication Critical patent/JP2021523125A5/ja
Application granted granted Critical
Publication of JP7458032B2 publication Critical patent/JP7458032B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020561786A 2018-05-03 2019-05-03 出血およびセンタキンによる蘇生後のエンドセリン受容体の変化 Active JP7458032B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862666675P 2018-05-03 2018-05-03
US62/666,675 2018-05-03
IN201841019588 2018-05-25
IN201841019588 2018-05-25
PCT/US2019/030652 WO2019213558A1 (en) 2018-05-03 2019-05-03 Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin

Publications (4)

Publication Number Publication Date
JP2021523125A JP2021523125A (ja) 2021-09-02
JPWO2019213558A5 JPWO2019213558A5 (https=) 2022-05-13
JP2021523125A5 JP2021523125A5 (https=) 2022-05-13
JP7458032B2 true JP7458032B2 (ja) 2024-03-29

Family

ID=68386694

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020561786A Active JP7458032B2 (ja) 2018-05-03 2019-05-03 出血およびセンタキンによる蘇生後のエンドセリン受容体の変化

Country Status (9)

Country Link
US (1) US20210169978A1 (https=)
EP (2) EP3813942B1 (https=)
JP (1) JP7458032B2 (https=)
CN (1) CN112469474A (https=)
AU (1) AU2019262612B2 (https=)
BR (1) BR112020022395A2 (https=)
ES (1) ES2978951T3 (https=)
PL (1) PL3813942T3 (https=)
WO (1) WO2019213558A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010241564B2 (en) 2009-04-30 2014-07-31 Midwestern University Novel therapeutic treatments using centhaquin
JP2024517334A (ja) * 2021-05-11 2024-04-19 ファーマズ，インコーポレイテッド コロナウイルス疾患（ｃｏｖｉｄ－１９）における急性呼吸窮迫症候群（ａｒｄｓ）の治療のための医薬組成物及び方法
US20240207356A1 (en) * 2022-12-26 2024-06-27 Pharmazz, Inc. Composition and method for wound healing and repair of damaged nerves
US20240382461A1 (en) * 2023-05-15 2024-11-21 Pharmazz, Inc. Pharmaceutical composition and method for prevention and treatment of hearing loss
IN202411028038A (https=) * 2024-04-04 2025-05-23

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019644A1 (fr) 1991-04-24 1992-11-12 Banyu Pharmaceutical Co., Ltd. Peptide vasodilatateur
JP2010523694A (ja) 2007-04-10 2010-07-15 オースペックス・ファーマシューティカルズ・インコーポレイテッド 高血圧治療のための置換重水素濃縮チオフェン
JP2010523584A (ja) 2007-04-02 2010-07-15 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換ピリミジン
JP2010536880A (ja) 2007-08-22 2010-12-02 ギリード・コロラド・インコーポレーテッド 糖尿病の合併症のための療法
JP2012525422A (ja) 2009-04-30 2012-10-22 ミッドウェスタン ユニバーシティ センタキンを用いた新規の治療方法
US20130296331A1 (en) 2010-11-26 2013-11-07 Technion Research And Development Foundation Ltd. Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury
JP2015530385A (ja) 2012-08-31 2015-10-15 ファーマズ，インコーポレイテッド 低血圧蘇生のための方法および組成物
JP2016523969A (ja) 2013-07-08 2016-08-12 ミッドウェスタン ユニバーシティ エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物及び方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2578709C (en) * 2004-06-17 2010-06-15 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
JP2009506119A (ja) * 2005-08-31 2009-02-12 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置
US9829494B2 (en) 2005-12-01 2017-11-28 Adrenomed Ag Methods of treatment using ADM antibodies

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019644A1 (fr) 1991-04-24 1992-11-12 Banyu Pharmaceutical Co., Ltd. Peptide vasodilatateur
JP2010523584A (ja) 2007-04-02 2010-07-15 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換ピリミジン
JP2010523694A (ja) 2007-04-10 2010-07-15 オースペックス・ファーマシューティカルズ・インコーポレイテッド 高血圧治療のための置換重水素濃縮チオフェン
JP2010536880A (ja) 2007-08-22 2010-12-02 ギリード・コロラド・インコーポレーテッド 糖尿病の合併症のための療法
JP2012525422A (ja) 2009-04-30 2012-10-22 ミッドウェスタン ユニバーシティ センタキンを用いた新規の治療方法
US20130296331A1 (en) 2010-11-26 2013-11-07 Technion Research And Development Foundation Ltd. Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury
JP2015530385A (ja) 2012-08-31 2015-10-15 ファーマズ，インコーポレイテッド 低血圧蘇生のための方法および組成物
JP2016523969A (ja) 2013-07-08 2016-08-12 ミッドウェスタン ユニバーシティ エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物及び方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MIGUEL, C. D. et al.，Endothelinreceptor-specific control of endoplasmic reticulum stress and apoptosis in thekidney，Sci. Rep.，2017年，vol. 7, 43152，p. 1-13
SRIMAL, R. C. et al.，Studies on 2-2-(4-(3-methylphenyl)1-piperazinyl)ethyl quinoline (centhaquin), a centrallyacting antihypertensive. II, Effect on cardiohaemodynamics，Asia pacific journal ofpharmacology，1990年，Vol 5, No. 3，pp 185-190
菱田 明，急性腎不全，日腎会誌，2002年，vol. 44, no. 2，p. 94-101

Also Published As

Publication number Publication date
EP3813942A1 (en) 2021-05-05
JP2021523125A (ja) 2021-09-02
EP3813942A4 (en) 2022-01-19
AU2019262612B2 (en) 2025-04-03
AU2019262612A1 (en) 2020-11-26
WO2019213558A1 (en) 2019-11-07
CA3099128A1 (en) 2019-11-07
US20210169978A1 (en) 2021-06-10
CN112469474A (zh) 2021-03-09
PL3813942T3 (pl) 2024-07-22
ES2978951T3 (es) 2024-09-23
EP3813942B1 (en) 2024-04-17
BR112020022395A2 (pt) 2021-04-13
EP4364811A2 (en) 2024-05-08
EP4364811A3 (en) 2024-07-10

Similar Documents

Publication Publication Date Title
JP7458032B2 (ja) 出血およびセンタキンによる蘇生後のエンドセリン受容体の変化
EP2890376B1 (en) Methods and compositions for hypotensive resuscitation
US20200375953A1 (en) Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists
KR100445946B1 (ko) 폐고혈압 치료법
CA3099128C (en) Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin
WO2021037212A9 (zh) 用于对抗代谢疾病的组合物及其用途
CN107243004B (zh) 一种五味子乙素在药物制备中的应用
JP6861162B2 (ja) アポエクオリン含有組成物および神経細胞の炎症を治療するためのアポエクオリンの使用方法
Abdallah New trends in pharmacological treatment of acute kidney injury
AU2017249459A1 (en) Treatment of renal cell carcinoma with lenvatinib and everolimus
CN117396505A (zh) 治疗炎症的方法
Briyal et al. Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin.
JP2019513727A (ja) レンバチニブ及びエベロリムスを用いた腎細胞癌の治療
AU2015203036A1 (en) Methods of Treating Hepatorenal Syndrom and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists
RU2785893C2 (ru) Лечение почечно-клеточной карциномы ленватинибом и эверолимусом
JP2019510777A (ja) Ｎｓａｉｄ誘発性の心血管、脳血管又は腎血管の有害事象を治療するための方法
KR20200139447A (ko) 항염증 조성물
Hsieh Pancreatic expression of trpa1, its role in insulin secretion and its possible effect on postprandial blood glucose levels
Buckley et al. Dr Maria Buckley, Department Pharmacology & Therapeutics, Department of Physiology, APC Microbiome Institute, University College Cork, Cork, Ireland.“Ghrelin enhances GLP-1 induced neuronal activation in the distal colon.”

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240308

R150 Certificate of patent or registration of utility model

Ref document number: 7458032

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150